Similarly, CD19+ JeKo-1 B lymphomas were killed only following administration of CD19-specific CAR T cells, but not untransduced or nontargeted EGFRvIII CAR T cells (Fig. 2 G; and Fig. S4, A–D). This evidence concerns the gene CD19 and lymphoma.